UniQure Plans Second Attempt at Impressing People Who Already Said No

UniQure will reapply for FDA approval of its Huntington's disease gene therapy. The company previously fought with the FDA over whether its clinical trial data was good enough. The FDA said no. UniQure disagreed publicly. Now UniQure is trying again.

Gene therapy companies love telling investors that one treatment will cure a disease forever. The pitch works great until the FDA asks for proof. Then it becomes a debate about what proof means. UniQure spent months arguing that its data was convincing. The FDA spent months being unconvinced. This is what happens when a biotech company mistakes confidence for evidence.

Huntington's disease destroys the brain over decades. Patients need real treatments. What they got instead was a public fight between a company and regulators over trial design. Nothing says cutting-edge medicine like two groups of scientists yelling at each other through press releases.

The stock moved on the announcement because biotech investors treat every regulatory filing like a lottery ticket. They bought shares hoping the FDA will reverse course and approve a therapy it already questioned. This strategy works exactly as often as you'd expect.

UniQure could have quietly addressed the FDA's concerns and resubmitted. Instead the company made the dispute public. That decision either signals supreme confidence in the data or supreme desperation for positive headlines. The Venn diagram of those two motivations is a circle.

Retail traders now own shares in a company that picked a fight with the one agency that decides whether it has a product. The FDA has a 100% approval rate over things the FDA approves. Everything else stays in the pipeline forever. UniQure is betting it can move from the second category to the first by filling out more paperwork and hoping the reviewers forgot about the argument.

The therapy either works or it doesn't. The data either shows efficacy or it doesn't. But we're all pretending the real issue is tone and presentation. Somewhere a Huntington's patient is watching this company relitigate its clinical trial in public and wondering why the f*ck the adults aren't in charge.

Photo by Brecht Corbeel on Unsplash